Literature DB >> 24060192

Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.

Justyna Pedowska-Włoszek1, Maciej Kostrubiec, Katarzyna Kurnicka, Michal Ciurzynski, Piotr Palczewski, Piotr Pruszczyk.   

Abstract

INTRODUCTION: According to current ESC guidelines not only hemodynamic parameters, but also indices of right ventricular dysfunction such as NT-proBNP have a significant prognostic value in acute pulmonary embolism (PE). MR-proADM is a significant predictor of short-term mortality in acute heart failure and adds prognostic value to NT-proBNP. We hypothesized that plasma MR-proADM is elevated in acute PE, correlates with the severity of PE and has prognostic value. We also compared prognostic values of MR-proADM and NT-proBNP for the prediction of early mortality in acute PE. MATERIAL &
METHODS: We studied 98 patients (51F/47M, 59.6 ± 18.4 yr) with acute PE. On admission blood samples were collected for MR-proADM and NT-proBNP.
RESULTS: MR-proADM reflected the severity of acute PE: 0.734 nmol/L in low-risk acute PE (0.384-1.342), 0.995 nmol/L in intermediate-risk acute PE (0.394-7.499) and 2.062 nmol/L in high-risk acute PE (0.447-3.098), p<0.001. MR-proADM was higher in non-survivors than in survivors 2.123 nmol/L (1.543-4.220), vs. 0.910 nmol/L (0.384-7.449), p=0.0003. The AUC of MR-proADM and NT-proBNP ROC curves for predicting all-cause mortality were 0.935 (95% CI 0.861-0.977) and 0.844 (95% CI 0.749-0. 913), respectively. In univariable analysis NT-proBNP and MR-proADM were significant predictors of all-cause mortality HR 1.00 (95% CI 1.000-1.0002, p=0.029) and 1.65 (95% CI 1.214 - 2.249, p=0.015). However, in multivariate analysis, MR-proADM but not NT-proBNP was a significant predictor of all-cause mortality.
CONCLUSION: NT-proBNP and MR-proADM are of similar predictive value in the assessment of outcome in acute PE, however MR-proADM seems to be superior in predicting all-cause mortality.
© 2013.

Entities:  

Keywords:  NTproBNP; acute pulmonary embolism; proadrenomedullin; prognosis

Mesh:

Substances:

Year:  2013        PMID: 24060192     DOI: 10.1016/j.thromres.2013.08.008

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Plasma copeptin for short term risk stratification in acute pulmonary embolism.

Authors:  Anna Wyzgał; Marcin Koć; Szymon Pacho; Maksymilian Bielecki; Radosław Wawrzyniak; Maciej Kostrubiec; Michał Ciurzyński; Katarzyna Kurnicka; Sylwia Goliszek; Marzena Paczyńska; Piotr Palczewski; Piotr Pruszczyk
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

2.  MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.

Authors:  Martin Kolditz; Hans-Jürgen Seyfarth; Heinrike Wilkens; Ralf Ewert; Tom Bollmann; Christiane Dinter; Sabine Hertel; Hans Klose; Christian Opitz; Ekkehard Grünig; Gert Höffken; Michael Halank
Journal:  Lung       Date:  2015-09-12       Impact factor: 2.584

3.  MR-proADM and MR-proANP levels in patients with acute pulmonary embolism.

Authors:  Önsel Öner; Figen Deveci; Selda Telo; Mutlu Kuluöztürk; Mehmet Balin
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

4.  Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study.

Authors:  Sara Graziadio; Rachel Amie O'Leary; Deborah D Stocken; Michael Power; A Joy Allen; A John Simpson; David Ashley Price
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

5.  Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea-a prospective intervention study.

Authors:  Meropi Karakioulaki; Peter Grendelmeier; Werner Strobel; Thomas Schmid; Kathleen Jahn; Leticia Grize; Michael Tamm; Daiana Stolz
Journal:  Respir Res       Date:  2021-04-20

6.  Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism.

Authors:  Nicolas Vuilleumier; Aurélien Simona; Marie Méan; Andreas Limacher; Pierre Lescuyer; Eric Gerstel; Henri Bounameaux; Drahomir Aujesky; Marc Righini
Journal:  PLoS One       Date:  2016-05-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.